Short Interest in NewGenIvf Group Limited (NASDAQ:NIVF) Declines By 89.7%

NewGenIvf Group Limited (NASDAQ:NIVFGet Free Report) saw a large decline in short interest in the month of July. As of July 15th, there was short interest totaling 67,374 shares, a decline of 89.7% from the June 30th total of 654,534 shares. Approximately 2.9% of the company’s shares are short sold. Based on an average daily trading volume, of 485,212 shares, the days-to-cover ratio is presently 0.1 days.

NewGenIvf Group Trading Down 9.8%

Shares of NewGenIvf Group stock traded down $0.12 during trading hours on Friday, hitting $1.10. The company’s stock had a trading volume of 176,396 shares, compared to its average volume of 934,198. NewGenIvf Group has a 12 month low of $1.10 and a 12 month high of $568.53. The stock has a 50 day moving average of $1.94 and a 200 day moving average of $7.11. The company has a quick ratio of 2.98, a current ratio of 3.12 and a debt-to-equity ratio of 0.16.

NewGenIvf Group (NASDAQ:NIVFGet Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($861.72) EPS for the quarter. The firm had revenue of $1.42 million during the quarter. Analysts anticipate that NewGenIvf Group will post 14.22 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Financial Lp Hrt purchased 45,847 shares of the stock in a transaction dated Friday, May 22nd. The stock was bought at an average cost of $2.97 per share, with a total value of $136,165.59. Following the purchase, the insider directly owned 37,295 shares in the company, valued at $110,766.15. The trade was a -536.10% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 31.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NIVF. Wall Street Zen raised shares of NewGenIvf Group to a “hold” rating in a research note on Saturday, July 4th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of NewGenIvf Group in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

View Our Latest Analysis on NIVF

NewGenIvf Group Company Profile

(Get Free Report)

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.

See Also

Receive News & Ratings for NewGenIvf Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewGenIvf Group and related companies with MarketBeat.com's FREE daily email newsletter.